Effect of topical and oral Resveratrol on skin health, condition and visible signs of ageing, in healthy ageing females.

This is a double-blind, randomised, placebo-controlled clinical study with an 8-week participation and 4 groups, assessing the effect of topical and oral Resveratrol on skin health, condition and visible signs of ageing, in healthy ageing females. Once enrolled in the trial, participants will be randomly allocated to one of the four treatment groups on a 1:4 chance basis. Baseline skin assessment and a fasting blood test (fasted for at least 10 hours excluding water) will be completed at enrolment. Skin assessment includes the characterization of fine lines/wrinkles, pore size, pigmentation area, sebum, moisture, elasticity and skin temperature. Prior to the skin assessment and photograph being taken, participants will remove all make-up and lipstick using provided make-up removal wipes, hair will be cleared away from the face. The fasting blood sample will measure oxidation markers, Resveratrol concentration and metabolites. Once the participant has completed the baseline measurements, they will be instructed to take/apply the allocated product according to the dose prescribed. Oral treatment (75 mg of Resveratrol per capsule. Total of 150mg of Resveratrol per day) will be taken twice daily in a single capsule with water (morning and evening). Topical treatment (1 g of cream containing 1.5% of Resveratrol) will be applied as 1g of cream topically morning and evening. During the 8-week study period, participants will be asked to attend the study site at midpoint (week 4) and the end of the study (week 8) to repeat baseline measurements. At the end of the study (week 8), participants will be asked to complete an exit interview (completed by trained trial coordinators) and questionnaire. Participants will be required to attend the study site in a fasted state during all visits. At the end of the 8 weeks, participation in the study will be considered complete. Participants will be monitored for compliance with the protocol by a combination of telephone and email communications in addition to during each scheduled visit.